International Journal of Inflammation (Jan 2022)

Alterations in Immune-Related Defensin Alpha 4 (DEFA4) Gene Expression in Health and Disease

  • Fatemah Basingab,
  • Abeer Alsaiary,
  • Shahad Almontashri,
  • Aisha Alrofaidi,
  • Mona Alharbi,
  • Sheren Azhari,
  • Khloud Algothmi,
  • Safiah Alhazmi

DOI
https://doi.org/10.1155/2022/9099136
Journal volume & issue
Vol. 2022

Abstract

Read online

Defensin Alpha 4 (DEFA4) is the fourth member of the Alpha Defensins family known as a part of antimicrobial peptides in the innate immune system. DEFA4 has a strong preference to kill Gram-negative bacteria more than Gram-positive bacteria. In addition, DEFA4 exhibits antiviral activity against human immunodeficiency virus type 1 (HIV-1) in vitro. Moreover, DEFA4 can act as an inhibitor of corticosterone production (Corticostatin). On the other hand, alternations in DEFA4 gene expression have been reported in different disorders such as diseases related to inflammation and immunity dysfunction, brain-related disorders, and various cancers. The up-regulation of DEFA4 appears to be involved in the malignant transformation or aggressive form of cancer. Interestingly, the modified version of DEFA4 fragment (1–11) was potent and efficient against antibiotic-resistant bacteria. This review provides a general background abSaudi Arabia out DEFA4 and sheds light on changes in DEFA4 gene expression in different diseases. The paper also discusses other aspects related to DEFA4 as an antimicrobial and antiviral agent. The research was conducted based on available articles obtained from databases starting from 1988 to the present.